High doses of β-blockers and alcohol abstinence improve long-term rebleeding andmortality in cirrhotic patients after an acute variceal bleeding

Liver International

Volumn 30, Issue 8, 2010, Pages 1123-1130

  Muntaner, Laura ^a,b   Altamirano, José Trinidad ^a,b   Augustin, Salvador ^a,b   González, Antonio ^a,b   Esteban, Rafael ^a,b   Guardia, Jaime ^a,b   Genesca, Joan ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

blocker therapy; Portal hypertension; Variceal bleeding

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ISOSORBIDE MONONITRATE; NADOLOL; NITRATE; SOMATOSTATIN;

ADULT; AGED; ALCOHOL ABSTINENCE; ALCOHOL LIVER CIRRHOSIS; ARTICLE; DEATH; ENDOSCOPIC SCLEROTHERAPY; ESOPHAGUS VARICES; ESOPHAGUS VARICES BLEEDING; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROPHYLAXIS; PROSPECTIVE STUDY; SURVIVAL TIME; VEIN LIGATION;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; ENDOSCOPY, GASTROINTESTINAL; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NADOLOL; REGRESSION ANALYSIS; TEMPERANCE;

EID: 79951615342     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02287.x     Document Type: Article

References (25)

1. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981; 80: 800-9.
2. Burroughs AK, Mezzanote G, Phillips A, et al. Cirrhotics with variceal hemorrhage: the importance of the time interval between admission and the start of analysis for survival and rebleeding rates. Hepatology 1989; 9: 801-7.
3. El-Serag HB, Everhart JE. Improved survival after variceal hemorrhage over an 11-year period in the Department of Veterans Affairs. Am J Gastroenterol 2000; 95: 3566-73.
4. Chalasani N, Kahi Ch, Francois F, et al. Improved patient survival after acute variceal bleeding: A multicenter cohort study. Am J Gastroenterol 2003; 98: 653-9.
5. Carbonell N, Pauwels A, Serfaty L, et al. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 2004; 40: 652-9.
6. Stokkeland K, Brandt L, Ekbom A, et al. Improved prognosis for patients hospitalized with esophageal varices in Sweden 1969-2002. Hepatology 2006; 43: 500-5.
7. D'Amico G, De Franchis R. Upper digestive bleeding in cirrhosis: post-therapeutic outcome and prognostic indicators. Hepatology 2003; 38: 599-612.
8. Cortez-Pinto H, Abrantes A, Esteves AV, et al. Long-term prognosis of patients with cirrhosis of the liver and upper gastrointestinal bleeding. Am J Gastroenterol 1989; 84: 1239-43.
9. Del Olmo JA, Peña A, Serra MA, et al. Predictors of morbidity and mortality after the first episode of upper gastrointestinal bleeding in liver cirrhosis. J Hepatol 2000; 32: 19-24.
10. De Franchis R, Pascal JP, Ancona E, et al. Definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol 1992; 15: 256-61.
11. De Franchis R. Developing consensus in portal hypertension. J Hepatol 1996; 25: 390-4.
12. Abraldes JG, Tarantino I, Turnes J, et al. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003; 37: 902-8.
13. D'Amico G, Garcia-Pagan J, Luca A, et al. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 2006; 131: 1611-24.
14. Allbillos A, Bañares R, González M, et al. Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis. Am J Gastroenterol 2007; 102: 1116-26.
15. Garcia-Tsao G, Sanyal AJ, Grace ND, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Practice Guidelines Committee of the American Association for the Study of Liver Diseases, the Practice Parameters Committee of the American College of Gastroenterology. Hepatology 2007; 46: 922-38.
16. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999; 19: 475-505.
17. González A, Augustin S, Perez M, et al. Hemodynamic response-guided therapy for prevention of variceal rebleeding: an uncontrolled pilot study. Hepatology 2006; 44: 806-12.
18. Poynard T, Lebrec D, Hillon P, et al. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a prospective study of factors associated with rebleeding. Hepatology 1987; 7: 447-51.
19. Lo GH, Chen WC, Lin CK, et al. Improved survival in patients receiving medical therapy as compared with banding ligation for the prevention of esophageal variceal bleeding. Hepatology 2008; 48: 580-7.
20. Thalheimer U, Bosch J, Burroughs AK. How to prevent varices from bleeding: shades of grey - the case for nonselective β-blockers. Gastroenterology 2007; 133: 2029-36.
21. Powell WJ, Klatskin G. Duration of survival in patients with Laennec's cirrhosis: Influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease. Am J Med 1968; 44: 406-20.
22. Borowsky SA, Strome S, Lott E. Continued heavy drinking and survival in alcoholic cirrhotics. Gastroenterology 1981; 80: 1405-9.
23. McCormick PA, Morgan MY, Phillips A, et al. The effects of alcohol use on rebleeding and mortality in patients with alcoholic cirrhosis following variceal haemorrhage. J Hepatol 1992; 14: 99-103.
24. Vorobioff J, Groszmann RJ, Picabea E, et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology 1996; 111: 701-9.
25. Villanueva C, Lopez-Balaguer JM, Aracil C, et al. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. J Hepatology 2004; 40: 757-65. Liver